Information Provided By: 
Fly News Breaks for September 22, 2015
ALNY
Sep 22, 2015 | 11:04 EDT
Piper Jaffray analyst Edward Tenthoff calls Alnylam Pharmaceuticals a victim of "Hillary-Scare" with the stock down for a second straight day. Hillary Clinton's proposal that would cap a patient's out-of-pocket prescription drug expense at $250 per month is unrealistic considering the value-add of innovative new therapies, Tenthoff tells investors in a research note. He recommends buying shares of Alnylam, which he views as a leading RNAi name with a "rich orphan drug pipeline."
News For ALNY From the Last 2 Days
There are no results for your query ALNY
